Vanda Pharmaceuticals (VNDA) EPS (Basic) Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Vanda Pharmaceuticals | 379.35 Mn | 177.04 Mn | 48.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -48.10% |
| Dec 31, 2025 | -78.13% |
| Sep 30, 2025 | -40.40% |
| Jun 30, 2025 | -37.28% |
| Mar 31, 2025 | -120.39% |
| Dec 31, 2024 | -25.59% |
| Sep 30, 2024 | -15.41% |
| Jun 30, 2024 | -18.77% |
| Mar 31, 2024 | -47.58% |
| Dec 31, 2023 | -17.61% |
| Sep 30, 2023 | -55.70% |
| Jun 30, 2023 | -19.73% |
| Mar 31, 2023 | -3.04% |
| Dec 31, 2022 | 37.97% |
| Sep 30, 2022 | 21.06% |
| Jun 30, 2022 | 29.67% |
| Mar 31, 2022 | 8.34% |
| Dec 31, 2021 | 71.88% |
| Sep 30, 2021 | 74.11% |
| Jun 30, 2021 | 28.81% |
| Mar 31, 2021 | 20.61% |
| Dec 31, 2020 | 19.54% |
| Sep 30, 2020 | 20.11% |
| Jun 30, 2020 | 26.43% |
| Mar 31, 2020 | 15.34% |
| Dec 31, 2019 | -46.64% |
| Sep 30, 2019 | 117.79% |
| Jun 30, 2019 | 18.57% |
| Mar 31, 2019 | 58.27% |
| Dec 31, 2018 | 23.47% |
| Sep 30, 2018 | 23.07% |
| Jun 30, 2018 | 22.42% |
| Mar 31, 2018 | 19.51% |
| Dec 31, 2017 | 29.52% |
| Sep 30, 2017 | 12.05% |
| Jun 30, 2017 | 36.03% |
| Mar 31, 2017 | 9.50% |
| Dec 31, 2016 | 45.07% |
| Sep 30, 2016 | 38.10% |
| Jun 30, 2016 | -17.08% |
| Mar 31, 2016 | -128.23% |
| Dec 31, 2015 | -44.27% |
| Sep 30, 2015 | -31.95% |
| Jun 30, 2015 | -35.69% |